Skip to main content
INSM logo

INSM · INSMED Inc · Webcasts, Transcripts & Audio

Track INSM — free
$123.82 +2.66 (+2.20%) Play latest call Q3 2026 earnings call transcript
Market Cap
$27.12B
Shares
219.38M
Volume · Nov 16 1.05M Avg daily vol (3M) 2.77M

INSMED Inc Webcasts

Earnings calls, investor updates, investor days and conferences for INSMED Inc (INSM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-12-01
INSMED Inc (INSM) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-16
INSMED Inc (INSM) November 16, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-10-29
INSMED Inc (INSM) Q3 2026 Earnings Call Transcript
Confident tone TPIP clinical development Brinsupri commercial momentum Brinsupri geographic expansion
Revenue
$524.43M
▲ 268.4% YoY
Diluted EPS
$-0.46
Gross margin
85.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-14
INSMED Inc (INSM) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
INSMED Inc (INSM) Q2 2026 Earnings Call Transcript
Confident tone Brinsupri commercial launch Revenue guidance raise Raised peak sales estimates
Revenue
$425.49M
▲ 296.1% YoY
Diluted EPS
$-0.06
Gross margin
84.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
INSMED Inc (INSM) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-20
INSMED Inc (INSM) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
INSMED Inc (INSM) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
INSMED Inc (INSM) Q1 2026 Earnings Call Transcript
Confident tone BRINSUPRI Commercial Launch Bronchiectasis Diagnosis Expansion / Disease Awareness TPIP Phase III Development
Revenue
$305.96M
▲ 229.6% YoY
Diluted EPS
$-0.76
Gross margin
84.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
INSMED Inc (INSM) Q4 2025 Earnings Call Transcript
Revenue
$263.84M*
▲ 152.6% YoY
Gross margin
83.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
INSMED Inc (INSM) Q3 2025 Earnings Call Transcript
Confident tone BRINSUPRI U.S. launch Payer access and reimbursement BiRCh Phase II in CRS without nasal polyps
Revenue
$142.34M
▲ 52.4% YoY
Diluted EPS
$-1.75
Gross margin
79.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
INSMED Inc (INSM) Q2 2025 Earnings Call Transcript
Confident tone Brensocatib U.S. launch and label/PDUFA TPIP Phase III planning across PAH, PH-ILD, IPF Pipeline label-expansion studies (BiRCh, CEDAR)
Revenue
$107.42M
▲ 18.9% YoY
Diluted EPS
$-1.70
Gross margin
73.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
INSMED Inc (INSM) Q1 2025 Earnings Call Transcript
Confident tone Brensocatib FDA review and bronchiectasis launch readiness TPIP Phase 2 in PAH ARIKAYCE commercial performance and ENCORE trial
Revenue
$92.82M
▲ 22.9% YoY
Diluted EPS
$-1.42
Gross margin
77.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
INSMED Inc (INSM) Q4 2024 Earnings Call Transcript
Confident tone Brensocatib launch readiness TPIP clinical development ARIKAYCE commercial performance
Revenue
$104.44M*
▲ 24.8% YoY
Gross margin
75.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
INSMED Inc (INSM) Q3 2024 Earnings Call Transcript
Confident tone Brensocatib NDA and launch preparation TPIP in PAH and PH-ILD ARIKAYCE commercial performance and ENCORE trial
Revenue
$93.42M
▲ 18.2% YoY
Diluted EPS
$-1.27
Gross margin
77.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
INSMED Inc (INSM) Q2 2024 Earnings Call
Revenue
$90.34M
▲ 17% YoY
Diluted EPS
$-1.94
Gross margin
76.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
INSMED Inc (INSM) Q1 2024 Earnings Call Transcript
Confident tone TPIP PH-ILD Phase II safety results TPIP PAH blinded Phase II data Brensocatib ASPEN Phase III readout
Revenue
$75.50M
▲ 15.8% YoY
Diluted EPS
$-1.06
Gross margin
76.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
INSMED Inc (INSM) Q4 2023 Earnings Call Transcript
Confident tone Brensocatib (ASPEN readout) and bronchiectasis opportunity TPIP program in PAH and PH-ILD Regulatory pathway and FDA engagement
Revenue
$83.69M*
▲ 41.1% YoY
Gross margin
78.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-26
INSMED Inc (INSM) Q3 2023 Earnings Call Transcript
Revenue
$79.07M
▲ 16.7% YoY
Diluted EPS
$-1.11
Gross margin
78.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
INSMED Inc (INSM) Q2 2023 Earnings Call Transcript
Revenue
$77.23M
▲ 18.4% YoY
Diluted EPS
$-1.78
Gross margin
78.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
INSMED Inc (INSM) Q1 2023 Earnings Call Transcript
Revenue
$65.21M
▲ 22.8% YoY
Diluted EPS
$-1.17
Gross margin
78.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
INSMED Inc (INSM) Q4 2022 Earnings Call Transcript
Revenue
$59.30M*
▲ 5.7% YoY
Gross margin
78.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-27
INSMED Inc (INSM) Q3 2022 Earnings Call Transcript
Revenue
$67.73M
▲ 44.9% YoY
Diluted EPS
$-1.09
Gross margin
80.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
INSMED Inc (INSM) Q2 2022 Earnings Call Transcript
Revenue
$65.22M
▲ 43.8% YoY
Diluted EPS
$-0.80
Gross margin
74.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
INSMED Inc (INSM) Q1 2022 Earnings Call Transcript
Revenue
$53.11M
▲ 32.1% YoY
Diluted EPS
$-0.80
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
INSMED Inc (INSM) Q4 2021 Earnings Call Transcript
Revenue
$56.12M*
▲ 35.5% YoY
Gross margin
76.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-28
INSMED Inc (INSM) Q3 2021 Earnings Call Transcript
Revenue
$46.76M
▲ 7.1% YoY
Diluted EPS
$-0.96
Gross margin
78.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
INSMED Inc (INSM) Q2 2021 Earnings Call Transcript
Revenue
$45.37M
▲ 6.8% YoY
Diluted EPS
$-1.07
Gross margin
76.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
INSMED Inc (INSM) Q1 2021 Earnings Call Transcript
Revenue
$40.21M
▲ 9.1% YoY
Diluted EPS
$-0.89
Gross margin
75.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
INSMED Inc (INSM) Q4 2020 Earnings Call Transcript
Revenue
$41.41M*
▼ 9.4% YoY
Gross margin
73.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-29
INSMED Inc (INSM) Q3 2020 Earnings Call Transcript
Revenue
$43.64M
▲ 12.2% YoY
Diluted EPS
$-0.63
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
INSMED Inc (INSM) Q2 2020 Earnings Call Transcript
Revenue
$42.49M
▲ 41.8% YoY
Diluted EPS
$-0.64
Gross margin
76.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
INSMED Inc (INSM) Q1 2020 Earnings Call Transcript
Revenue
$36.86M
▲ 68.3% YoY
Gross margin
77.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
INSMED Inc (INSM) Q4 2019 Earnings Call
Revenue
$45.71M
▲ 364.7% YoY
Gross margin
81.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–34 of 34 webcasts
Key facts CIK 1104506 CUSIP 457669307 13F (30d) 535 filings 488 filers Visit website Investor relations